NCT06889350

Pharmacokinetics and Safety of HD-P023 and Co-administration of Teneligliptin and Empagliflozin High in Healthy Volunteers

A Randomized, Open-label, Crossover, Phase 1 Study to Evaluate Pharmacokinetics and Safety of HD-P023 in Comparison With Co-administration of Teneligliptin and Empagliflozin High in Healthy Volunteers

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 40 (actual)
• Sponsor: Handok Inc. · Industry
• Sex: All
• Age: 19 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to compare the pharmacokinetics and safety of HD-P023 and coadministration of Teneligliptin and Empagliflozin in healthy adult volunteers

Conditions

• Healthy Volunteers

Interventions

Type	Name	Description
DRUG	HD-P023	Single dose administration of HD-P023
DRUG	Teneligliptin	Single does administration of Teneligliptin and Empagliflozin High
DRUG	Empagliflozin High	Single does administration of Teneligliptin and Empagliflozin High

Timeline

• Start date: 2025-03-26
• Primary completion: 2025-04-13
• Completion: 2025-05-07
• First posted: 2025-03-21
• Last updated: 2025-07-31

Locations

1 site across 1 country: South Korea